AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca PLC (NASDAQ:AZN) faces potential headwinds from the Inflation Reduction Act (IRA) and VBP in China, which could ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a probe into alleged legal breaches tied to drug importation and data ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting ...

During an open workout ahead of their highly publicized boxing match, Mike Tyson and Jake Paul both describe their emotions ahead of fight night.

PS5 Push play to the max, turn the ordinary into the extraordinary. Go all in with PS5. Play Has No Limits. #playstation5 ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...